Oncology Cancer Drugs Market

1
Oncology Cancer Drugs Market
2
Summary

• Oncology (1985-2016) - 157 cancer drugs  -
  Ranking and detailed regulatory approval
  profiles is a comprehensive drug ranking and
  profiling report that ranks cancer drugs based on
  total approvals and unique approvals received in
  US, Europe and Japan. It provides the regulatory
  approval details of each drug for the past 30
  years (1985-2016) in both the tabular and (an
  interesting) infographic formats. Additionally,
  the basic drug-specific information such as first
  approvals, breakthrough,
• orphan designations, black box warnings, etc., is
  also
• presented along with negative developments of
  drugs
• recalled, discontinued and withdrawn.

3
(No Transcript)
4
Part 1 The basic information section covers

• Trade names Drugs are often known by different
  brand names (trade names) in different
  geographies. For instance, Rituxan is the trade
  name for Rituximab in the US, whereas it is known
  as Mabthera in Europe. We have presented each
  drugs trade name used in different geographies
  in our report.Companies involved in marketing
  Drugs are often sold or
• marketed in different geographies by different
  companies.
• For instance, Aranesp is marketed in the US and
  Europe by
• Amgen, whereas in Japan it is marketed by
• Kyowa Hakko Kirin.

5

• Active pharmaceutical ingredient Active
  pharmaceutical ingredients (API) are the active
  ingredients in medications, carried by the
  excipient. In each case, the drug has an API and
  it has a trade name, by which it is known in the
  market. For instance, Revlimid is the brand or
  trade name, whereas lenalidomide is its
  API.Therapy segment We have classified drugs
  into five
• major therapy segments - Targeted, Chemo,
  Hormone,
• Vaccines and Adjuvants. For instance, Herceptin
  is a
• Targeted Therapy drug whereas Zytiga is a Hormone
  
• Therapy drug.

6

• Immuno-oncology This is a growing area of cancer
  therapy. We have highlighted whether the drugs
  classified fall under this category or not. For
  instance, Opdivo is an immuno-oncology
  drug.Class of drug Various therapy segments are
  further classified into classes of drugs.
  Monoclonal antibodies, tyrosine kinase and
  alkylating agent are examples of classes of
  drugs. Yervoy is a monoclonal antibody whereas
• Tarceva is a tyrosine kinase inhibitor.

7

• Molecule type Drugs are classified into two
  categories,
• small and large, on the basis of their molecular
  weight
• greater than 900 daltons are large molecules and
  less than
• 900 daltons are small molecules. Large molecules
  are
• also known as biological drugs.
•  
• Dosage form We have explained whether the dosage
  is in
• the form of vials/injections (injectable) or
  tablets/capsules
• (oral). For instance, Tecentriq is an injectable
  drug whereas
• Thalomid is an oral tablet.

8

• Route of administration We have explained
  whether the drug is taken orally or through the
  intravenous route. For instance, Empliciti (for
  multiple myeloma) is taken through the
  intravenous route.Mechanism of action The term
  mechanism of action refers to the specific
  biochemical interaction through which a drug
  substance
• produces its pharmacological effect. A mechanism
  of
• action usually includes mention of the specific
  molecular
• targets to which the drug binds, such as an
  enzyme
• or receptor.

9

• First approved indication in the geographies US,
  EU and Japan Many cancer drugs are often
  approved for more than one indication. We have
  highlighted the first approved indication of each
  drug in the various geographies. For instance,
  Xeloda was first approved for metastatic breast
  cancer in the US and Japan whereas, in Europe,
• it was first approved for colorectal cancer.

10
Full Report Oncology Cancer Drugs Market

• Bharat Book Bureau
• Tel [phone]
• Email poonam_at_bharatbook.com
• Website www.bharatbook.com
• FaceBook BharatBook3B
• Twitter ResearchBook
• LinkedIn Bharat Book Bureau